Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about CAH, unsubscribe in one click. Privacy
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Chlorella | Diabetes | N/A · NCT01301287 | Unknown |
| 14-day Cerebrolysin treatment | Intracerebral Hemorrhage | Phase 4 · NCT06899464 | Not yet recruiting |
| Drug: G.S.P. Solution 400 mg/ml I.V. 1.2 | Galactose Single Point (GSP), Residual Liver Funct | Phase 1/2 · NCT04546022 | Completed |
| Loxoprofen Pain Patch | Delayed Onset Muscle Soreness | Phase 2 · NCT02602353 | Completed |
| Technetium Tc 99m-labeled Tilmanocept | Anal Cancer | Phase 2 · NCT02857608 | Withdrawn |
| No Treatment | Delayed Onset Muscle Soreness | Phase 2 · NCT02602353 | Completed |
| Isosulfan Blue | Rhabdomyosarcoma | Phase 2 · NCT02509598 | Completed |
Also used in these trials (approved or third-party drugs, not CAH's own candidates): Simvastatin, Empagliflozin, Cisplatin, Nivolumab, Pembrolizumab.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
CAH holds $4.9B in cash and short-term investments (as of Jun 30, 2026) and its operations are currently cash-flow neutral or positive.
Dilution pressure: 0 · Low
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when CAH files for a raise →
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CAH and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →